Skip to main content
Veterinary Medicines

Aderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg

Authorised
  • Milbemycin oxime
  • Praziquantel

Product identification

Medicine name:
Aderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg
Active substance:
  • Milbemycin oxime
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    12.50
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    125.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Authorisation status:
  • Valid
Authorised in:
  • United Kingdom (Northern Ireland)
Package description:
  • Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil.Cardboard box with 1 blister of 2 tablets.
  • Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil.Cardboard box with 1 blister of 4 tablets.
  • Blister packs consisting of cold formed OPA/Al/PVC foil and aluminium foil.Cardboard box with 12 blisters, each blister contains 4 tablets (total 48 tablets).

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Tad Pharma GmbH
  • Krka d.d. Novo Mesto
Responsible authority:
  • The Veterinary Medicines Directorate
Authorisation number:
  • VM 24745/4024
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0528/002
Concerned member states:
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."